

Bölüm 11

KASTRASYON DİRENÇLİ PROSTAT KANSERİNDE RADYONÜKLİD TEDAVİNİN YERİ

Gülcan BULUT¹

GİRİŞ

Radyoizotop tedaviler kastrasyona dirençli prostat kanserinde semptomatik kemik metastazına yönelik tedaviler arasında yer alır. Bu tedavi için ön şart ağrılı kemik lokalizasyonu ile uyumlu kemik taramasıdır. Radyoligand tedaviler ileri prostat kanseri ve osteoblastik kemik metastazı olan hastalarda kullanılır. Kemiğe yönelik radyoisotopların en bilineni Radium-223 'dür. Daha çok nöroendokrin tümörlerin tedavisinde kullanılan radyoligand tedavilerden Lutesyum 177 prostat spesifik membran antijenine bağlanarak geliştirilmesi ile prostat kanser tedavisinde de kullanılmaya başlandı.

1. KEMİĞE YÖNELİK RADYOİSOTOP TEDAVİLER:

1a)Alfa Işını Yayan Radyo-isotoplar:

Radium -223; alfa ışını yayan bir radyofarmasötiktir.(1) Radium kemik arayan bir elementtir ve radyum -223 izotopun; beta ışını yayan diğer izotoplara göre daha kısa dalga boylu olması sebebiyle kemik iliği ve diğer organ toksisitesi daha azdır. (2)

Radium-223 'ün kemik metastazı olup bilinen visseral metastazı olmayan hastalarda yapılan Faz 3 ALSYMCA çalışmasında tedavinin iyi tolere edildiği ve hem genel sağkalımda hem de iskelet ilişkili olayın (Radyoterapi gerekliliği, yeni semptomatik patolojik fraktür, spinalkord sıkışması veya tümörle ilgili ortopedik operasyon gerekliliği) gerçekleşme süresinde uzuma görüldü. Etki mekanizması nedeniyle kullanımı sınırlıdır.(3) ALSYMCA faz 3 çalışmasında tüm hastalar kastrasyon dirençliydi ve tüm hastalarda iki veya daha fazla kemik metastazı olması, visseral metastazın olmaması gerekiyordu. Çalışmaya alınan hastalar ya dosetaksele aday olamayan ya da dosetaksel alıp progrese olanlardan oluşuyordu. Toplamda 921 hasta plesebo ya karşı 2: 1 oranında randomize edildi. Dört haftada bir 6 seans radyum-223 uygulandı. Plesebo kolunda olan hastalarda ikinci

¹ Dr., Necip Fazıl Şehir Hastanesi, Tıbbi Onkoloji, gulcanbulut07@gmail.com

KAYNAKLAR :

1. Parker C, Nilsson S, Heninrich D. et al. Alpha emitter Radium-223 and survival in metastatic prostat cancer. *N Engl J Med.* 2013 Jul;369(3):213-23.
2. Sartor O, Coleman R, Nilsson S et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. *Lancet Oncol.* 2014;15(7):738. Epub 2014 May 13.
3. Hoskin P, Sartor O, O'Sullivan JM et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. *Lancet Oncol.* 2014;15(12):1397.
4. Parker CC, Coleman RE, Sartor O, et al Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alphasradin in Symptomatic Prostate Cancer Trial *Eur Urol.* 2017
5. Sternberg CN, Saad F, Graff JN, et al. A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride in bone metastatic castration-resistant prostate cancer (abstract 5008). *American Society of Clinical Oncology annual meeting* 2018.
6. Sartor O, Heinrich D, Mariados N et al. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. *Ann Oncol.* 2017;28(10):2464
7. Saad F, Carles J, Gillessen S et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. *Lancet Oncol.* 2016;17(9):1306. Epub 2016 Jul 26
8. Etchebehere EC, Milton DR, Araujo JC et al. Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution. *Eur J Nucl Med Mol Imaging.* 2016 Jan;43(1):8-20. Epub 2015 Sep 29
9. <https://www.prnewswire.com/news-releases/phase-iii-trial-of-radium-ra-223-dichloride-in-combination-with-abiraterone-acetate-and-prednisone-prednisolone-for-patients-with-metastatic-castration-resistant-prostate-cancer-unblinded-early-300564844.html> (Accessed on December 13, 2017).
10. Smith MR, Parker CC, Saad F, et al. ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone predominant metastatic castration-resistant prostate cancer (LBA30). Data presented at the 2018 meeting of the European Society for Medical Oncology (ESMO), Munich Germany, October 23, 2018.
11. Morris MJ, Higano CS, Scher HI, et al. Effects of radium-223 dichloride (Ra-223) with docetaxel (D) versus D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial (abstract). *J Clin Oncol* 33, 2015 (suppl 7; abstr 202).
12. Liepe K, Kotzerke J et al. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. *Nucl Med Commun.* 2007;28(8):623.

13. Porter AT, McEwan AJ, Powe JE et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. *Int J Radiat Oncol Biol Phys.*
14. Quilty PM, Kirk D, Bolger JJ et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. *Radiother Oncol.* 1994;31(1):33.
15. Oosterhof GO, Roberts JT, de Reijke TM et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormone escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. *Eur Urol.* 2003;44(5):519.
16. James ND, Pirrie SJ, Pope AM et al. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial. *JAMA Oncol.* 2016;2(4):493
17. Serafini AN, Houston SJ, Resche I et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. *J Clin Oncol.* 1998;16(4):1574.
18. Fendler WP, Rahbar K, Herrmann K et al. ¹⁷⁷Lu-PSMA Radioligand Therapy for Prostate Cancer. *J Nucl Med.* 2017;58(8):1196. Epub 2017 Jun 29.
19. Hofman MS, Violet J, Hicks RJ et al. (¹⁷⁷Lu)-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. *Lancet Oncol.* 2018;19(6):825. Epub 2018 May 8.
20. Rahbar K, Ahmadzadehfar H, Kratochwil C et al. German Multicenter Study Investigating ¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. *J Nucl Med.* 2017;58(1):85. Epub 2016 Oct 20.